$OREX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Orexigen Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Orexigen Therapeutics, Inc.. Get notifications about new insider transactions in Orexigen Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 04 2019 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Option Exercise | J | 15.00 | 100,000,000 | 1,500,000,000 | 0 | |
Jun 04 2019 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Option Exercise | J | 60.00 | 5,000,000 | 300,000,000 | 0 | |
Oct 31 2018 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Sell | S | 0.01 | 896,339 | 8,963 | 0 | 896.3 K to 0 (-100.00 %) |
Oct 31 2018 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Sell | S | 0.01 | 650,000 | 6,500 | 896,339 | 1.5 M to 896.3 K (-42.03 %) |
Oct 26 2018 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Sell | S | 0.01 | 652,500 | 6,525 | 1,546,339 | 2.2 M to 1.5 M (-29.67 %) |
Oct 26 2018 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Sell | S | 0.01 | 28,000 | 280 | 2,198,839 | 2.2 M to 2.2 M (-1.26 %) |
Apr 26 2018 | OREX | Orexigen Therapeut ... | BAUPOST GROUP LLC/MA | 10% Owner | Option Exercise | J | 7.50 | 16,483,517 | 123,626,378 | 7,802,197 | |
Mar 16 2018 | OREX | Orexigen Therapeut ... | Moglia Stephen A. | VP & Chief Accounti ... | Sell | S | 0.24 | 1,694 | 407 | 0 | 1.7 K to 0 (-100.00 %) |
Oct 17 2017 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP, Chief Admin Of ... | Option Exercise | A | 0.00 | 69,600 | 0 | 69,600 | |
Oct 17 2017 | OREX | Orexigen Therapeut ... | Keyes Jason A | EVP, Chief Financia ... | Option Exercise | A | 0.00 | 69,600 | 0 | 69,600 | |
Oct 17 2017 | OREX | Orexigen Therapeut ... | Flynn Peter D | EVP, Head of Global ... | Option Exercise | A | 0.00 | 69,600 | 0 | 69,600 | |
Oct 17 2017 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, COO, Pres Glob ... | Option Exercise | A | 0.00 | 91,200 | 0 | 91,200 | |
Oct 17 2017 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 0.00 | 252,000 | 0 | 252,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | MAHAFFY PATRICK J | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | JORN DEBORA | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | Honig Peter | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | Endicott David J. | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jul 18 2017 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
Jun 02 2017 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Grant | A | 1.55 | 626 | 970 | 8,356 | 7.7 K to 8.4 K (+8.10 %) |
Jun 02 2017 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Grant | A | 1.55 | 1,704 | 2,641 | 1,704 | 0 to 1.7 K |
Jun 02 2017 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Grant | A | 1.55 | 557 | 863 | 3,031 | 2.5 K to 3 K (+22.51 %) |
Jun 02 2017 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, COO, Pres Glob ... | Grant | A | 1.55 | 2,119 | 3,284 | 3,882 | 1.8 K to 3.9 K (+120.19 %) |
Feb 07 2017 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 15.00 | 157,500 | 2,362,500 | 157,500 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 4.10 | 315,000 | 1,291,500 | 315,000 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 15.00 | 43,500 | 652,500 | 43,500 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 4.10 | 87,000 | 356,700 | 87,000 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Option Exercise | A | 15.00 | 43,500 | 652,500 | 43,500 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Option Exercise | A | 4.10 | 87,000 | 356,700 | 87,000 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Flynn Peter D | SVP, Dev, Reg Affa ... | Option Exercise | A | 15.00 | 43,500 | 652,500 | 43,500 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Flynn Peter D | SVP, Dev, Reg Affa ... | Option Exercise | A | 4.10 | 87,000 | 356,700 | 87,000 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, COO, Pres Glob ... | Option Exercise | A | 15.00 | 72,000 | 1,080,000 | 144,000 | |
Feb 07 2017 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, COO, Pres Glob ... | Option Exercise | A | 4.10 | 144,000 | 590,400 | 144,000 | |
Dec 21 2016 | OREX | Orexigen Therapeut ... | Moglia Stephen A. | VP, Chief Accountin ... | Sell | S | 1.96 | 800 | 1,568 | 0 | 800 to 0 (-100.00 %) |
Dec 02 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Grant | A | 1.67 | 802 | 1,339 | 6,312 | 5.5 K to 6.3 K (+14.56 %) |
Dec 02 2016 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Grant | A | 1.67 | 291 | 486 | 2,474 | 2.2 K to 2.5 K (+13.33 %) |
Dec 02 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, COO, Pres Glob ... | Grant | A | 1.67 | 291 | 486 | 1,763 | 1.5 K to 1.8 K (+19.77 %) |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 15.00 | 15,750 | 236,250 | 15,750 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 15.00 | 78,750 | 1,181,250 | 78,750 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 4.02 | 26,250 | 105,525 | 26,250 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 4.02 | 131,250 | 527,625 | 131,250 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Option Exercise | A | 15.00 | 15,750 | 236,250 | 15,750 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Option Exercise | A | 15.00 | 78,750 | 1,181,250 | 78,750 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Option Exercise | A | 4.02 | 26,250 | 105,525 | 26,250 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Keyes Jason A | SVP, Chief Financia ... | Option Exercise | A | 4.02 | 131,250 | 527,625 | 131,250 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Flynn Peter D | SVP, Dev, Reg Affa ... | Option Exercise | A | 15.00 | 15,750 | 236,250 | 15,750 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Flynn Peter D | SVP, Dev, Reg Affa ... | Option Exercise | A | 15.00 | 78,750 | 1,181,250 | 78,750 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Flynn Peter D | SVP, Dev, Reg Affa ... | Option Exercise | A | 4.02 | 26,250 | 105,525 | 26,250 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Flynn Peter D | SVP, Dev, Reg Affa ... | Option Exercise | A | 4.02 | 131,250 | 527,625 | 131,250 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Option Exercise | A | 15.00 | 31,500 | 472,500 | 31,500 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Option Exercise | A | 15.00 | 157,500 | 2,362,500 | 157,500 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Option Exercise | A | 4.02 | 52,500 | 211,050 | 52,500 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Option Exercise | A | 4.02 | 262,500 | 1,055,250 | 262,500 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 15.00 | 63,000 | 945,000 | 63,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 15.00 | 315,000 | 4,725,000 | 315,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 4.02 | 105,000 | 422,100 | 105,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 4.02 | 525,000 | 2,110,500 | 525,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Moglia Stephen A. | VP, Chief Accountin ... | Option Exercise | A | 15.00 | 28,800 | 432,000 | 28,800 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Moglia Stephen A. | VP, Chief Accountin ... | Option Exercise | A | 4.02 | 48,000 | 192,960 | 48,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | MAHAFFY PATRICK J | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | JORN DEBORA | Director | Option Exercise | A | 4.02 | 16,500 | 66,330 | 16,500 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Honig Peter | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | Endicott David J. | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jul 14 2016 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
Jun 02 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Grant | A | 0.34 | 8,777 | 2,984 | 69,285 | 60.5 K to 69.3 K (+14.51 %) |
Jun 02 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Grant | A | 0.34 | 9,632 | 3,275 | 14,723 | 5.1 K to 14.7 K (+189.20 %) |
May 24 2016 | OREX | Orexigen Therapeut ... | JORN DEBORA | Director | Option Exercise | A | 0.40 | 70,000 | 28,000 | 70,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Moglia Stephen A. | VP, Chief Accountin ... | Option Exercise | A | 0.00 | 90,000 | 0 | 90,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Moglia Stephen A. | VP, Chief Accountin ... | Option Exercise | A | 1.78 | 65,000 | 115,700 | 65,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | ACE HEATHER S | EVP, Global Human R ... | Option Exercise | A | 0.00 | 225,000 | 0 | 225,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 0.00 | 255,000 | 0 | 255,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Klassen Preston | EVP, Global Develop ... | Option Exercise | A | 0.00 | 350,000 | 0 | 350,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Klassen Preston | EVP, Global Develop ... | Option Exercise | A | 1.78 | 190,000 | 338,200 | 190,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Klassen Preston | EVP, Global Develop ... | Grant | A | 2.03 | 4,170 | 8,465 | 10,160 | 6 K to 10.2 K (+69.62 %) |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Klassen Preston | EVP, Global Develop ... | Grant | A | 4.17 | 1,860 | 7,756 | 5,990 | 4.1 K to 6 K (+45.04 %) |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Option Exercise | A | 0.00 | 350,000 | 0 | 350,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Option Exercise | A | 1.78 | 390,000 | 694,200 | 390,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | Cannell Thomas R | EVP, Chief Commerci ... | Grant | A | 2.03 | 5,091 | 10,335 | 5,091 | 0 to 5.1 K |
Feb 04 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 0.00 | 800,000 | 0 | 800,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Option Exercise | A | 1.78 | 700,000 | 1,246,000 | 700,000 | |
Feb 04 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Grant | A | 2.03 | 1,761 | 3,575 | 60,508 | 58.7 K to 60.5 K (+3.00 %) |
Feb 04 2016 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | CEO & President | Grant | A | 4.17 | 721 | 3,007 | 58,747 | 58 K to 58.7 K (+1.24 %) |
Feb 04 2016 | OREX | Orexigen Therapeut ... | ACE HEATHER S | EVP, Global Human R ... | Option Exercise | A | 1.57 | 325,000 | 510,250 | 325,000 | |
Dec 02 2015 | OREX | Orexigen Therapeut ... | Lynch Thomas P. | EVP. General Counse ... | Option Exercise | A | 2.29 | 350,000 | 801,500 | 350,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | MAHAFFY PATRICK J | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | Honig Peter | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | Endicott David J. | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | DIXON WENDY L | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | WEBER ECKARD | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Mar 31 2015 | OREX | Orexigen Therapeut ... | Cannell Thomas R | Chief Commercial Of ... | Option Exercise | A | 7.75 | 425,000 | 3,293,750 | 425,000 | |
Mar 02 2015 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | M | 1.66 | 50,000 | 83,000 | 563,924 | |
Mar 02 2015 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Sell | S | 5.68 | 50,000 | 284,200 | 3,810 | 53.8 K to 3.8 K (-92.92 %) |
Mar 02 2015 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Buy | M | 1.66 | 50,000 | 83,000 | 53,810 | 3.8 K to 53.8 K (+1,312.34 %) |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | A | 5.34 | 153,050 | 817,287 | 153,050 | |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | A | 5.34 | 88,925 | 474,860 | 88,925 | |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Grant | A | 5.25 | 4,218 | 22,145 | 8,028 | 3.8 K to 8 K (+110.71 %) |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | A | 5.34 | 202,650 | 1,082,151 | 202,650 | |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | A | 5.34 | 182,650 | 975,351 | 182,650 | |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Grant | A | 4.92 | 1,542 | 7,587 | 4,130 | 2.6 K to 4.1 K (+59.58 %) |
Feb 05 2015 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Grant | A | 5.25 | 1,318 | 6,920 | 2,588 | 1.3 K to 2.6 K (+103.78 %) |
Feb 05 2015 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | A | 5.34 | 635,150 | 3,391,701 | 635,150 | |
Dec 04 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | M | 1.66 | 22,643 | 37,587 | 656,932 | |
Dec 04 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Sell | S | 6.00 | 22,643 | 135,858 | 0 | 22.6 K to 0 (-100.00 %) |
Dec 04 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Buy | M | 1.66 | 22,643 | 37,587 | 22,643 | 0 to 22.6 K |
Nov 26 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | M | 1.66 | 7,382 | 12,254 | 679,575 | |
Nov 26 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Option Exercise | M | 1.66 | 24,006 | 39,850 | 686,957 | |
Nov 26 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Sell | S | 6.00 | 7,382 | 44,292 | 0 | 7.4 K to 0 (-100.00 %) |
Nov 26 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Buy | M | 1.66 | 7,382 | 12,254 | 7,382 | 0 to 7.4 K |
Nov 26 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Sell | S | 5.77 | 24,006 | 138,587 | 0 | 24 K to 0 (-100.00 %) |
Nov 26 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | SVP, Gen. Counsel & ... | Buy | M | 1.66 | 24,006 | 39,850 | 24,006 | 0 to 24 K |
Nov 20 2014 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Buy | P | 5.58 | 700 | 3,905 | 700 | 0 to 700 |
Nov 20 2014 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Buy | P | 5.58 | 625 | 3,487 | 27,677 | 27.1 K to 27.7 K (+2.31 %) |
Nov 13 2014 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Buy | P | 5.57 | 27,052 | 150,544 | 27,052 | 0 to 27.1 K |
Sep 22 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | VP, Gen. Counsel & ... | Option Exercise | M | 1.66 | 300,000 | 498,000 | 710,963 | |
Sep 22 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | VP, Gen. Counsel & ... | Sell | S | 4.47 | 300,000 | 1,339,500 | 0 | 300 K to 0 (-100.00 %) |
Sep 22 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | VP, Gen. Counsel & ... | Buy | M | 1.66 | 300,000 | 498,000 | 300,000 | 0 to 300 K |
Sep 15 2014 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Buy | P | 4.78 | 50,000 | 239,100 | 58,026 | 8 K to 58 K (+622.98 %) |
Sep 15 2014 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Sr. VP, Corporate D ... | Buy | P | 4.69 | 5,000 | 23,450 | 13,026 | 8 K to 13 K (+62.30 %) |
Jun 30 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | Endicott David J. | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | MAHAFFY PATRICK J | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | BOCK LOUIS C | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | Honig Peter | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | DIXON WENDY L | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Jun 27 2014 | OREX | Orexigen Therapeut ... | WEBER ECKARD | Director | Option Exercise | A | 5.97 | 50,000 | 298,500 | 50,000 | |
Apr 23 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | M | 0.00 | 7,882 | 8 | 0 | |
Apr 23 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Option Exercise | M | 0.00 | 461,265 | 461 | 0 | |
Apr 23 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Payment of Exercise | F | 5.30 | 15 | 80 | 129,448 | 129.5 K to 129.4 K (-0.01 %) |
Apr 23 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Buy | M | 0.00 | 78,820 | 79 | 129,463 | 50.6 K to 129.5 K (+155.64 %) |
Apr 23 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Payment of Exercise | F | 5.30 | 871 | 4,616 | 7,579,194 | 7.6 M to 7.6 M (-0.01 %) |
Apr 23 2014 | OREX | Orexigen Therapeut ... | DOVEY BRIAN H | Director | Buy | M | 0.00 | 4,612,650 | 4,613 | 7,580,065 | 3 M to 7.6 M (+155.44 %) |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | VP, Gen. Counsel & ... | Option Exercise | A | 6.30 | 205,000 | 1,291,500 | 205,000 | |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Turner Heather D | VP, Gen. Counsel & ... | Grant | A | 5.34 | 3,980 | 21,253 | 3,980 | 0 to 4 K |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | A | 6.30 | 225,000 | 1,417,500 | 225,000 | |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Grant | A | 5.34 | 3,980 | 21,253 | 3,980 | 0 to 4 K |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Option Exercise | A | 6.30 | 205,000 | 1,291,500 | 205,000 | |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Klassen Preston | SVP, Head Global De ... | Grant | A | 5.34 | 1,270 | 6,782 | 1,270 | 0 to 1.3 K |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Option Exercise | A | 6.30 | 205,000 | 1,291,500 | 205,000 | |
Feb 11 2014 | OREX | Orexigen Therapeut ... | Booth Mark D | Chief Commercial Of ... | Grant | A | 5.34 | 3,810 | 20,345 | 3,810 | 0 to 3.8 K |
Feb 11 2014 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Option Exercise | A | 6.30 | 673,500 | 4,243,050 | 673,500 | |
Feb 11 2014 | OREX | Orexigen Therapeut ... | NARACHI MICHAEL | President and CEO | Grant | A | 5.34 | 3,980 | 21,253 | 3,980 | 0 to 4 K |
Aug 02 2013 | OREX | Orexigen Therapeut ... | Hagan Joseph P | Chief Business Offi ... | Option Exercise | M | 1.66 | 12,000 | 19,920 | 764,000 |